| Home  | About ScienceAsia  | Publication charge  | Advertise with us  | Subscription for printed version  | Contact us  
Editorial Board
Journal Policy
Instructions for Authors
Online submission
Author Login
Reviewer Login
Volume 49 Number 4
Volume 49 Number 3
Volume 49 Number 2
Volume 49 Number 1
Volume 48 Number 6
Volume 48 Number 5
Earlier issues
Volume 48 Number 5 Volume 48 Number 6 Volume 49 Number 1

previous article next article

Research articles

ScienceAsia 48 (2022): 734-739 |doi: 10.2306/scienceasia1513-1874.2022.111

Dexmedetomidine promotes cell proliferation and attenuates insulin resistance in high glucose induced trophoblast cells via inactivating the p38 MAPK pathway

Xiaofeng Song*, Zhiqiang Shao, Ping Xu

ABSTRACT:     Gestational diabetes mellitus (GDM) is a disease that occurs during pregnancy. Promoting the proliferation and migration of trophoblast cells and increasing insulin sensitivity are the strategies to improve GDM. Dexmedetomidine (DEX) is a highly selective ? 2-adrenoceptor agonist with sedative and analgesic effects and has been widely used in clinical anesthesia. However, the exact effect of DEX on GDM is still unclear. In this study, the effects of DEX on the progression of GDM were investigated. A high glucose (HG) cell model was constructed via treating Human trophoblast cell line HTR-8/SVneo with 25 mmol/l glucose. The results showed that DEX promoted HTR-8/SVneo cell proliferation of high glucose induced cells and suppressed the apoptosis. In addition, DEX promoted insulin sensitivity in hTR-8 /SVneo cells induced by high glucose. Mechanically, DEX suppressed the p38 MAPK pathway in hTR-8/SVneo cells, resulting in stimulation of cell proliferation and suppression of insulin resistance. In conclusion, these results suggested that DEX promotes cell proliferation and attenuates insulin resistance in GDM.

Download PDF

79 Downloads 898 Views

a Department of Anesthesiology, Fuyang Health Hospital for Women and Children, Hangzhou, Zhejiang 311400 China

* Corresponding author, E-mail: songxiaofeng_0220@163.com

Received 23 Feb 2022, Accepted 4 Jun 2022